Last updated: February 27, 2026
What is the drug associated with NDC 00378-2350?
NDC 00378-2350 corresponds to Zepzelca (Lurbinectedin), developed by Pharma Mar. It is an oncology medication approved by the FDA for the treatment of metastatic small cell lung cancer (SCLC) with disease progression following platinum-based chemotherapy.
Market Overview
Regulatory Status
- FDA Approval: June 2020 under accelerated approval.
- Indication: Treatment of adult patients with metastatic SCLC approved for use post-chemotherapy progression.
- Additional Approvals: EMA approval pending or under review in some regions; no other major approvals confirmed as of now.
Market Size
- U.S. Small Cell Lung Cancer (SCLC) Incidence (2022): Approximately 30,000 new cases annually (American Cancer Society).
- Relapsed SCLC Market: Estimated to constitute 50-60% of SCLC patients, translating to roughly 15,000-18,000 patients eligible for second-line therapy.
- Market Penetration: Predicted usage in 20-40% of relapsed/ refractory cases initially, depending on clinician adoption and reimbursement.
Competitive Landscape
| Drug Name |
Approval Year |
Mechanism of Action |
Price (Average Wholesale Price) |
Market Share (2022 forecast) |
| Zepzelca |
2020 |
Lurbinectedin |
$12,000 per 3.2 mg vial |
~15-20% in relapsed SCLC |
| Topotecan |
1987 |
Topoisomerase inhibitor |
$200 per 4 mg vial |
Dominates second-line therapy |
| Lurbinectedin (Zepzelca) |
2020 |
DNA minor groove binder |
$12,000 per vial |
Growing, estimated to reach 30% in future |
Price Points
- Current Pricing: Zepzelca's wholesale acquisition cost (WAC) for a 3.2 mg vial is approximately $12,000. Treatment regimens often involve 2-4 doses, leading to a total treatment cost of roughly $24,000 to $48,000.
- Reimbursement: Coverage widely available through Medicare and private insurers, subject to formulary restrictions.
Market Trends
- Adoption Rates: As of 2023, Zepzelca is gradually gaining adoption in relapsed SCLC, especially among patients who tolerate and respond to initial therapy.
- Physician Acceptance: High efficacy signals and manageable safety profile bolster growth prospects, but competition from established agents like topotecan limits rapid market share gains.
- Pricing Impact: Its high price is a barrier for some payers, but Value-based pricing negotiations are ongoing.
Price Projections (Next 5 Years)
| Year |
Estimated Price (per vial) |
Expected Market Share |
Annual Revenue Estimate |
Rationale |
| 2023 |
$12,000 |
15% |
$350 million |
Initial uptake, limited by reimbursement and clinician familiarity |
| 2024 |
$12,000 |
20% |
$550 million |
Growing acceptance, expanded payer coverage |
| 2025 |
$12,000 |
25% |
$750 million |
Increased prescriber confidence, imminent competition impact |
| 2026 |
$11,500 - $12,000 |
30% |
$900 million - $1 billion |
Price competition and negotiated discounts may influence pricing |
| 2027 |
$11,000 - $12,000 |
35% |
$1 billion - $1.2 billion |
Market saturation, potential generics or biosimilars not expected |
Note: These projections assume stable drug prices with minor negotiations and no major market disruptions.
Key Opportunities and Risks
Opportunities
- Expansion into broader SCLC populations.
- Use in combination regimens.
- Use in other solid tumors with similar DNA repair deficiencies.
Risks
- Slow uptake due to high costs.
- Competition from emerging therapies or new agents.
- Regulatory delays or restrictions.
Key Takeaways
- NDC 00378-2350 (Zepzelca) targets a niche in relapsed SCLC.
- Currently priced at ~$12,000 per vial; total treatment costs range from $24,000 to $48,000.
- Market penetration remains modest but steady, with revenue forecasted to reach over $1 billion by 2027.
- Competitive landscape favors early adoption and payer engagement.
- Long-term growth depends on clinical expansion, pricing strategies, and pipeline developments.
FAQs
1. What is the primary indication for NDC 00378-2350?
Treatment of metastatic small cell lung cancer after progression following platinum-based chemotherapy.
2. How does Zepzelca’s price compare to similar drugs in SCLC?
It is substantially higher—around $12,000 per vial—compared to older agents like topotecan, which costs approximately $200 per vial.
3. What is the expected market share over the next five years?
Growth from around 15% in 2023 to approximately 35% in 2027 among relapsed cases.
4. What limits the drug’s pricing and adoption?
High cost and reimbursement restrictions, as well as slow clinician adoption due to competition and existing standards of care.
5. Are there any upcoming regulatory or market developments?
Potential FDA or EMA approvals for expanded indications, and strategies to negotiate price and improve payer engagement will influence future market dynamics.
References
- American Cancer Society. (2022). Cancer facts & figures 2022. https://cancer.org
- FDA. (2020). Zepzelca (Lurbinectedin) Prescribing Information. https://fda.gov
- IQVIA. (2022). Market data and drug pricing reports. IQVIA.
- Pharma Mar. (2020). Zepzelca (Lurbinectedin) approval announcement. https://pharmamar.com
- Statista. (2022). Small cell lung cancer incidence rates. https://statista.com
